Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

International Journal of Molecular Sciences

Yosuke Minami¹  Kenichi Miyamoto¹ 

[1] Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan;

关键词: acute myeloid leukemia;    FMS-like tyrosine kinase 3;    isocitrate dehydrogenase;    immune checkpoint inhibitor;    chimeric antigen receptor;   

DOI  :  10.3390/ijms21145114

来源: DOAJ

【 摘 要 】

Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML.

【 授权许可】

Unknown